الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
The pharmacokinetic profile of cefoperazone was studied in goats following i.v and i.m administration of 20 mg/kg b.wt. Cefoperazone concentrations in serum were determined by microbiological assay technique using Escherichia coli (ATCC 10536). Following i.v administration, the cefoperazone serum concentration-time curve was best fitted in a two compartment open model. Cefoperazone has moderate distribution in the body of goats with Vdss of 0.47 L/kg. The (T0.5β), (AUC) and (Cltot) were 2.2 h, 138.4 µg/ml/h, and 0.145 ±0.004 L/kg/h, respectively. Following i.m administration, the drug was very rapidly absorbed, with (T0.5ab) of 0.11 ± 0.03 h. The (Cmax) of 30.96 µg/ml was attained at (Tmax) 0.58 h, with an elimination half-life (T0.5el) of 2.4 h. The systemic bioavailability of cefoperazone in the goats after i.m administration was 95.8% and in vitro protein binding was 27.1%. The serum concentrations of cefoperazone along 12 h post i.m injection in this study were exceeding the MIC of different susceptible micro-organisms responsible for serious disease problems. Consequently, a suitable intramuscular dosage regimen for cefoperazone was 20 mg/kg repeated at 12 h intervals in goats. The drug was detected in urine up to 12 and 18 h following i.v and i.m administration, respectively. Following intramuscular injection of 20 mg/kg.b.wt of cefoperazone twice daily for 5 consecutive days, cefoperazone showed a minimal cumulative behaviour in serum, urine and milk of normal goats. Results of this study indicated that nitroxynil altered the pharmacokinetic profile of cefoperazone as it decreased the (T0.5el), (Cmax) and the MRT of cefoperazone, consequently decrease its efficacy.